Perth's Sir Charles Gairdner Hospital and Fiona Stanley Hospital manage significant prostate cancer patient populations across Western Australia. For Perth patients not meeting PBS eligibility criteria or seeking private treatment, generic Abiranamo 250mg offers identical clinical benefit to brand Zytiga at dramatically lower cost.
Western Australia's mining industry workforce — predominantly male with an ageing demographic — contributes to significant prostate cancer incidence across the state. Abiranamo's mechanism of blocking CYP17A1 androgen synthesis continues to deliver survival benefit for mCRPC patients who have progressed on standard androgen deprivation therapy.
Western Australia's mining industry workforce — predominantly male with an ageing demographic — contributes to significant prostate cancer incidence across the state. Abiranamo's mechanism of blocking CYP17A1 androgen synthesis continues to deliver survival benefit for mCRPC patients who have progressed on standard androgen deprivation therapy.
What is the difference between mCRPC and hormone-sensitive prostate cancer, and does Abiranamo treat both?Hormone-sensitive prostate cancer (also called castration-sensitive) still responds to standard androgen deprivation therapy (ADT) — the cancer cells still depend on testosterone and respond to its removal. Metastatic castration-resistant prostate cancer (mCRPC) has evolved mechanisms to grow despite castrate testosterone levels — through androgen receptor mutations, alternative androgen synthesis pathways, or other resistance mechanisms. Abiraterone was originally approved specifically for mCRPC, where it blocks alternative androgen production. More recently, it has also demonstrated benefit in metastatic hormone-sensitive prostate cancer when combined with ADT, so in current practice it's used in both settings, though PBS/reimbursement criteria differ.
